- Case report
- Open Access
- Open Peer Review
Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report
© Wong et al.; licensee BioMed Central Ltd. 2012
- Received: 23 March 2012
- Accepted: 26 June 2012
- Published: 31 August 2012
Vasculitis has been associated with malignancies, more commonly hematological rather than solid malignancies. Due to the rarity of these conditions and the lack of a temporal association, the relationship between vasculitis and malignancy remains unclear. Paraneoplastic vasculitis as a phenomenon of lung cancer has been described in the literature. To the best of our knowledge, this is the first case report of leukocytoclastic vasculitis being an initial presentation of malignant pleural mesothelioma.
We report the case of an 84-year old Greek man who presented to our facility with an erythematous, pruritic and purpuric rash affecting his limbs. This was biopsy-proven to be leukocytoclastic vasculitis and treated conservatively with topical corticosteroids as well as oral prednisolone, with good results. Six months later, he was diagnosed as having malignant pleural mesothelioma. As he remained asymptomatic from his malignancy, no systemic chemotherapy was instituted. He had a recurrence of biopsy-proven leukocytoclastic vasculitis two months after he was diagnosed as having mesothelioma, which again settled with conservative measures.
It is important to remain vigilant with regard to the association between leukocytoclastic vasculitis and malignancies. A diagnosis of vasculitis requires a search for malignancies as well as other possible etiologies. This is particularly of relevance when the vasculitis becomes chronic, recurrent or treatment is no longer effective. Should our patient have experienced refractory vasculitis, we would have instituted systemic chemotherapy to treat the underlying malignancy.
- Leukocytoclastic vasculitis
Leukocytoclastic vasculitis (LCV) is a small-vessel inflammatory disease mediated by deposition of immune complexes. It usually occurs in the setting of an underlying process, such as medication exposure, infection, malignancy, connective tissue disease or as a manifestation of a primary systemic vasculitis . Vasculitis has been associated more commonly with hematological rather than solid malignancies . The mechanism by which malignancies cause vasculitis remains unclear. This report illustrates a rare case of paraneoplastic LCV as an initial presentation of malignant pleural mesothelioma (MPM).
Six months later, he presented again with a right-sided pleural effusion that contained atypical mesothelial cells on drainage, raising the suspicion of MPM. A subsequent video-assisted thoracoscopic surgery biopsy confirmed biphasic MPM involving the parietal pleura. Laboratory tests demonstrated thrombocytosis of 628 × 109 cells/L (normal range: 150×109 cells/L to 400 × 109 cells/L), elevated C-reactive protein of 293.3mg/L (normal range: <8mg/L) and ESR of 58mm/hour (normal range: 5 to 12mm/hour). A computed tomography scan of the chest revealed right lower lobe collapse and difficulty assessing for a mass lesion.
As he was otherwise asymptomatic, he declined systemic chemotherapy. Two months after being diagnosed as having MPM, he had a recurrence of biopsy-confirmed LCV that again responded to oral prednisolone and topical corticosteroids. The MPM and LCV have not required further treatment, such as chemotherapy, as our patient remains asymptomatic.
LCV is a small-vessel vasculitis featuring leukocytoclasia of infiltrating granulocytes with fibrinoid necrosis of the vascular wall and subsequent extravasation of erythrocytes . The clinical hallmark of LCV includes erythematous macules and urticarial papules, sometimes progressing to palpable purpura, which is usually symmetric but can be diffuse as well . In more than 70% of cases, LCV occurs in the setting of an underlying process inclusive of medication exposure, infection, malignancy, connective tissue disease or as a manifestation of a primary systemic vasculitis . It is classified as idiopathic vasculitis once other etiologies have been excluded.
The occurrence of vasculitis with malignancy has been postulated for many years. It has been estimated that about 5% of patients with vasculitis may have an underlying related malignancy . One retrospective review  identified 69 patients with both cancer and malignancy over an 18.5-year period. There were only 12 patients in whom the diagnosis of malignancy and vasculitis occurred within a 12-month period. The most common vasculitis was cutaneous LCV, which occurred in seven cases, with four of them being solid organ malignancies. There was no observed predictable response of vasculitis to treatment with glucocorticoids and systemic chemotherapy. In comparison, a retrospective review conducted by Fain et al. identified 60% of their patients (n=60) with vasculitis and malignancy within a 12-month period. LCV was again the most common vasculitis, accounting for 45% of all patient cases. Their review reported one case of mesothelioma associated with vasculitis.
To the best of our knowledge, there have been no previously reported cases of paraneoplastic leukocytoclastic vasculitis occurring with MPM. Our case illustrates that vasculitis may not only be the presenting feature of MPM but may even precede the diagnosis by a number of months. Failure of LCV to respond to usually effective therapies should prompt a search for underlying malignancy. Treatment of paraneoplastic LCV should be directed at the underlying malignancy or by using a combination of corticosteroids and immunosuppresants, especially in the case of hemorrhagic blisters or incipient skin necrosis .
We report a case of paraneoplastic LCV as the initial presentation of MPM. To the best of our knowledge, this is the first case report of LCV presenting with MPM. Corticosteroid treatment dramatically improved the cutaneous LCV in our patient. Should the LCV have been steroid refractory, systemic chemotherapy was considered the next option. However, this has not been required to date and our patient remains well without evidence of progression eight months after diagnosis.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Langford CA: Vasculitis. J Allergy Clin Immunol. 2010, 125: S216-S225. 10.1016/j.jaci.2009.07.002.View ArticlePubMedGoogle Scholar
- Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS: Vasculitis associated with malignancy. Experience with 13 patients and literature review. Medicine (Baltimore). 1988, 67: 220-230.View ArticleGoogle Scholar
- Sunderkotter C, Bonsmann G, Sindrilaru A, Luger T: Management of leukocytoclastic vasculitis. J Dermatolog Treat. 2005, 16: 193-206. 10.1080/09546630500277971.View ArticlePubMedGoogle Scholar
- Swerlick R, Lawley T: Cutaneous vasculitis: its relationship to systemic disease. Med Clin North Am. 1989, 73: 1221-1235.View ArticlePubMedGoogle Scholar
- Hayem G, Gomez M, Grossin M, Meyer O, Kahn M: Systemic vasculitis and epithelioma: a report of three cases with a literature review. Rev Rhum Eng Ed. 1997, 64: 816-824.Google Scholar
- Hutson TE, Hoffman GS: Temporal concurrence of vasculitis and cancer: a report of 12 cases. Arthritis Care Res. 2000, 13: 417-423. 10.1002/1529-0131(200012)13:6<417::AID-ART13>3.0.CO;2-T.View ArticlePubMedGoogle Scholar
- Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Pariès J, Stirnemann J, Morin AS, Gatfosse M, Hanslik T, Belmatoug N, Blétry O, Cevallos R, Delevaux I, Fisher E, Hayem G, Kaplan G, Le Hello C, Mouthon L, Larroche C, Lemaire V, Piette AM, Piette JC, Ponge T, Puechal X, Rossert J, Sarrot-Reynauld F, Sicard D, Ziza JM, Kahn MF: Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007, 57: 1473-1480. 10.1002/art.23085.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.